<DOC>
	<DOCNO>NCT01109433</DOCNO>
	<brief_summary>Background : - Uveitis , inflammation interior eye , responsible numerous new case legal blindness every year . Uveitis cause Beh ( SqrRoot ) ( Beta ) et disease ( BD ) , chronic inflammatory disorder affect eye , mucous membrane , body organ joint , intestinal tract , blood vessel , central nervous system . Objectives : The purpose study see gene affect Beh ( SqrRoot ) ( Beta ) et disease difference Beh ( SqrRoot ) ( Beta ) et disease among people different background . Eligibility : - Individuals diagnosis BD enrol another NIH study . - Individuals willing donate blood purpose research study willing blood store possible future/other research purpose . Design : - As part study , blood sample draw participant exacerbation disease activity occur significant change treatment BD . - No treatment provide study .</brief_summary>
	<brief_title>Immunogenetic Mechanisms Behcet 's Disease</brief_title>
	<detailed_description>Uveitis responsible approximately 30,000 case new legal blindness United States 2.8-10 % case blindness . Beh ( SqrRoot ) ( Beta ) et disease ( BD ) chronic relapse multisystem inflammatory disorder unknown etiology characterize intraocular inflammation , oral mucosal ulceration , cutaneous lesion inflammation may affect body organs joint , intestinal tract , epididymis , blood vessel central nervous system ( 2 ) . The need safer effective therapy patient ocular manifestation BD refractory intolerant systemic immunosuppressive therapy warrant investigation . Reports define specific role interleukin ( IL ) -17A pathogenesis Beh ( SqrRoot ) ( Beta ) et disease . This protocol evaluate immune mediator include cytokine profile ( soluble intracellular ) , lymphocyte phenotyping regulatory T-cells participant BD . Epigenetic modification also study . Additionally , suggest American/Western BD patient may different disease characteristic Mediterranean counterpart . The disease characteristic American/Western Mediterranean BD patient compare evaluated . Blood sample BD participant participate NIH protocol participant consent future use sample obtain collected ( particularly current participant NIH protocol 03-AR-0173 NEI collaborator ) . In summary , result analyze respect disease different ethnic group , clinical feature disease ( e.g. , ocular vs. non-ocular involvement , active vs. quiescent disease ) . Anonymous blood sample ( match race , age sex ) obtain NIH clinical center ( CC ) blood bank compare diseased sample .</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Behcet Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA : One follow must true : Participants must diagnosis BD accord International Study Group BD criterion modify Japanese criterion , enrol another NIH study willing donate blood purpose research study . Participants must willing blood store future/other research . EXCLUSION CRITERIA : Eligible participant wish donate blood sample undergo blood draw purpose research study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 6, 2017</verification_date>
	<keyword>Behcet 's Disease</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Uveitis</keyword>
	<keyword>Immunogenetics</keyword>
</DOC>